AAAlexandre Acramel

Alexandre Acramel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandre Acramel has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Synthèse d'inhibiteurs potentiels de la voie de GPER : application au cancer du sein triple négatif

    by Alexandre Acramel

    Le cancer du sein triple négatif (CSTN) représente environ 15 % des cancers du sein et se caractérise par l'absence d'expression des récepteurs hormonaux (ER, PR) et d'amplification du récepteur HER2. Cette forme particulièrement agressive touche chaque année près de 9 000 femmes en France, avec un taux de rechute élevé et un pronostic défavorable. Les traitements conventionnels, reposant essentiellement sur des chimiothérapies cytotoxiques peu spécifiques, exposent les patientes à des effets indésirables importants et n'apportent pas de bénéfice durable pour une majorité d'entre elles. Depuis peu, des traitements ciblant TROP2 (sacituzumab govitécan) ou PD-1 (pembrolizumab) sont indiqués à des stades avancés de la maladie. À ce jour, aucune cible moléculaire exploitée cliniquement n'a été validée pour une prise en charge thérapeutique précoce. Dans ce contexte, le GPER (G protein-coupled estrogen receptor), récepteur membranaire couplé aux protéines G activé par l'œstradiol, émerge comme une cible thérapeutique prometteuse. Ce récepteur est surexprimé dans plus de 60 % des tumeurs de CSTN et son expression est corrélée à la taille tumorale, au stade clinique et à la présence de métastases, suggérant un rôle actif dans la progression tumorale. Le GPER active des voies de signalisation non génomiques (EGFR/ERK/MAPK, PI3K/Akt), favorisant la prolifération, la migration et la survie des cellules tumorales. Étant donné leur spécificité pour GPER, trois dérivés quinoléiques sont considérés comme des ligands de référence lors des études qui s'intéressent au GPER : G-1 (agoniste), G-15 (antagoniste) et G-36 (antagoniste). Cette thèse s'inscrit ainsi dans une démarche de conception rationnelle de médicaments innovants en oncologie, combinant modélisation moléculaire, synthèse organique et validation pharmacologique. Par des méthodes in silico (docking, pharmacophores, dynamique moléculaire) des interactions clefs entre les ligands envisagés et les résidus de la poche de liaison (Leu137, Glu275, Phe314) ont été identifiées. Sur cette base, des séries originales de dérivés trans-chalcones, 2-benzylidène-1-tétralones, 3-benzylidène-4-chromanones et leurs 2-pyrazolines respectives, tous porteurs du pharmacophore bromobenzodioxole, commun aux quinoléines G-1, G-15 et G-36. Une quarantaine de composés ont été testés in vitro sur la lignée de CSTN MDA-MB-231. En grande majorité, ces dérivés ont montré une activité antiproliférative marquée à des concentrations micromolaires (0,1-10 µM). Un dérivé 2-benzylidène-1-tétralone (5a) s'est distingué par une activité atténuée dans les cellules MDA-MB-231 GPER KO, suggérant une dépendance fonctionnelle à GPER. Des études mécanistiques ont permis d'exclure l'implication des voies EGFR, ERK, MEK, PI3K/Akt, c-fos et du protéasome, suggérant un nouveau mode d'action. Des relations structure-activité ont pu être établies, mettant en évidence l'importance du brome pour l'ancrage au site canonique du GPER, et du dioxolane pour l'activité antiproliférative dose-dépendante. L'analogue tétralone 5a le plus actif a été évalué in vivo sur un modèle murin de xénogreffe de CSTN, où il a démontré une réduction de la croissance tumorale comparable au paclitaxel par rapport au véhicule. Ces travaux confortent l'intérêt du GPER comme cible thérapeutique dans le CSTN et positionnent les dérivés 2-benzylidène-1-tétralones comme une nouvelle classe de modulateurs de GPER à visée anticancéreuse.

  • Reducing waiting time of injectable anticancer drug preparations in day care oncology units: A summary of evidence, implemented strategies, and perspectives for hospital pharmacists

    by Jean-Stéphane Giraud, Mélanie Brun, Romain Desmaris, Paul Cottu, Alexandre Acramel

    Objective: With the increasing incidence of cancer worldwide, injectable anticancer agents are being increasingly prescribed for outpatients in day care oncology units. These drugs are prepared in hospital pharmacy cytotoxic units. This paper explores delay factors and pharmacist-led solutions to reduce patients’ waiting time for antitumor treatment infusion in day care cancer hospitals. Data Sources: A literature review was carried out using PubMed and other sources, including conference abstracts and relevant publications. The main search terms included “chemotherapy,” “waiting time,” “oncology,” “outpatient,” “pharmacy,” “pharmacist,” and “satisfaction,” combined with AND/OR operators. Available data were analyzed and complemented by our pharmaceutical and clinical expertise. Data Summary: Based on published works, we examined the negative impacts of delays on patients’ well-being, the role of hospital pharmacists in decreasing these delays and provided our perspective. Discussion: Cancer patients already face multiple emotional and physical challenges. Long waiting time can further heighten patients’ anxiety and stress. Delays in the delivery of anticancer infusions can be caused by various factors, including logistical problems, drug supply delays, and administrative issues. To minimize these delays, several initiatives can be implemented, such as efficient treatment planning, early prescription and preparation in advance, robotization to enhance productivity, proactive lean management, and improved communication between care teams. Conclusions: It is important for hospital pharmacists to define a dispensing time for injectable anticancer treatments and monitor it as a quality indicator. Collaboration between pharmacists and physicians to establish this critical threshold will help optimize care and improve the patient's experience.

  • Gravimetric-based technology-assisted workflow system for injectable anticancer drugs compounding: Design and qualification of an original weighing scale anchored inside an isolator

    by Mélanie Brun, Julien Fouque, Hugo Palisson, Mallory Friou, Audrey Hurgon, Laurence Escalup, Laetitia Le, Alexandre Acramel

    Technology-assisted manufacturing such as computer-assisted gravimetric control (CAGC) is a well-established method for injectable anticancer drugs (AD) compounding. The aim of this study was to validate an innovative weighing scale (WS) anchored inside an isolator for in-process gravimetric control (GC) of injectable AD compounding in a French Comprehensive Cancer Centre. The weighing scale studied Cyto-TopControl ® was designed by hospital pharmacists and the manufacturer LDI. Operational and performance qualification were carried out using weights ranging from 1 to 2000 g to assess fidelity, accuracy, linearity, eccentricity, precision and inter-test precision. The performance of the Cyto-TopControl ® were compared to the standard WS model Cytocontrol ® (LDI) by using a Bland-Altman plot. Infusion bags of four drugs (paclitaxel, docetaxel, epirubicin and trastuzumab) were then compounded by using CAGC associated with this new WS. For each preparation, an analytical control (AC) was carried out to validate the GC as a reference method. A total of 1530 weighings were performed. The maximum tolerated deviation and the accuracy deviations were not exceeded for each of the weights studied (® and CytoControl ® were consistent. Sixty bags were manufactured with the accuracy of 0.19% for GC and 5.07% for AC. This work confirms the reliability of this innovative WS for the in-process GC of injectable AD compounding.

  • Open Access

    Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach

    by Alexandre Acramel, Sandy Blondeel‐Gomes, Mathilde Dupré, Ornella Tangila Kayembe, Aude Rochereau, Laurence Escalup, Romain Desmaris, Nathalie Jourdan, Adeline Cordary, Pauline Vaflard, et al.

    Aims: The purpose of this work was to assess failures in the advanced prescription of parenteral anticancer agents in an adult day oncology care unit with more than 100 patients per day.Methods: An a priori descriptive analysis was carried out by using the risk matrix approach. After defining the scope in a multidisciplinary meeting, we determined at each step the failure modes (FMs), their effects (E) and their associated causes (C). A severity score (S) was assigned to all effects and a probability of occurrence (O) to all causes. These S and O indicators, were used to obtain a criticality index (CI) matrix. We assessed the risk control (RC) of each failure in order to define a residual criticality index (rCI) matrix.Results: During risk analysis, 14 FMs were detected, and 61 scenarios were identified considering all possible effects and causes. Nine situations (15%) were highlighted with the maximum CI, 18 (30%) with a medium CI, and 34 (55%) with a negligible CI. Nevertheless, among all these critical situations, only three (5%) had an rCI to process (i.e., missed dose adjustment, multiple prescriptions and abnormal biology data); the others required monitoring only. Clinicians' and pharmacists' knowledge of these critical situations enables them to manage the associated risks.Conclusions: Advanced prescription of injectable anticancer drugs appears to be a safe practice for patients when combined with risk management. The major risks identified concerned missed dose adjustment, prescription duplication and lack of consideration for abnormal biology data.


  • Errors in prescribing injectable anticancer drugs: benefits of a pharmaceutical long-term monitoring to improve patient safety in a European comprehensive cancer centre

    by Mathilde Dupre, Laurence Escalup, Sandy Blondeel-Gomes, Pauline Vaflard, Romain Desmaris, Paul Cottu, Alexandre Acramel

    Objectives We aimed to assess the impact of pharmacist interventions on injectable chemotherapy prescription and the safety of early prescription practice in an adult daily care unit. Methods Prescription errors were recorded before and after implementing corrective measures. Errors identified from the pre-intervention period (i) were analysed to identify areas for improvement. During the post-intervention period (ii) we compared the errors in anticipated prescription (AP) with those in real-time prescriptions (RTP). We performed Chi-square statistical tests (α=0.05). Results Before implementing corrective measures (i), 377 errors were recorded (ie, 3.02% of prescriptions). After the implementation of corrective measures (ii), there was a significant decrease in errors, with 94 errors recorded (ie, 1.20% of prescriptions). The error rate in AP and RTP groups was 1.34% and 1.02%, respectively, without a significant difference between the two groups. Conclusions This study highlights the importance of prescription review, as well as collaboration between pharmacists and physicians, in reducing prescription errors, whether these prescriptions were anticipated or not.


  • Open Access

    Reporting environmental contamination results to healthcare workers could play a crucial role in decreasing the risk of occupational exposure to antineoplastic drugs

    by Alexandre Acramel, Sandy Blondeel-Gomes, Carla Matta, Subramanian Narayani, Olivier Madar, Romain Desmaris, Laurence Escalup, Julien Fouque

    Reporting environmental contamination results to healthcare workers could play a crucial role in decreasing the risk of occupational exposure to antineoplastic drugs


  • Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center

    by Alexandre Acramel, Julien Fouque, Sandy Blondeel-Gomes, Samuel Huguet, Keyvan Rezai, Olivier Madar, Laurence Escalup

    The risk of chronic exposure to antineoplastic agents in hospitals, mainly by skin contact with contaminated surfaces, is well established. The aim of this study was to assess indirectly the risk of occupational exposure to antineoplastics drugs at two hospitals by using an environmental monitoring, and to suggest ways of improving the exposure to healthcare workers. An observational study of care practices on both sites was carried out. A wipe sampling campaign was then designed to study environmental contamination throughout the chemotherapy process: receipt, storage, compounding, transport, administration, and elimination areas. Samples were analyzed by a validated LC-MS/MS method allowing trace quantification of cyclophosphamide. A guidance ‘safe value’ of 0.10 ng/cm2 was considered. A total of 293 samples were analyzed, of which 58% were found to be positive. In the compounding units, the drug vials were contaminated before [range = (non-quantifiable [NQ]-0.71) ng/cm2] and after cleaning procedure [(NQ-0.62) ng/cm2], particularly when the flip-off lid was removed during cleaning. The contamination found on manual preparations was operator-dependent: [non-detectable (ND)-3.51] ng/cm2 on infusion bag surfaces; (780.61–24 698.98) ng/cm2 on medication ports. In the case of automated preparations, the average contamination was higher on infusion bag surfaces [(2.43–36.86) ng/cm2] and lower on medication ports [(0.43–7.65) ng/cm2] than manual preparations. Contamination of the analytical control area was also highlighted. In the daily care unit, the contamination was located near the infusion area (armchairs, infusion stands, floor, and patient toilets), and varied somewhat between the two sites, especially on the floor with (0.46–27.32) compared to (ND-0.18) ng/cm2. We did not detect contamination on the transport boxes, on the door handles or in the disposal areas. The variability of contamination observed between the two sites can be explained in part by the difference in routine practices, especially training of the staff, and cleaning procedures. Findings were communicated to healthcare workers, and news interventions were implemented based on wipe sampling results. This study demonstrated a method for routine environmental monitoring and worker education as a strategy to reduce occupational exposure.


  • Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples

    by Alexandre Acramel, Thibaut Chouquet, Alain Plé, Hélène Sauvageon, Samia Mourah, Fanélie Jouenne, Lauriane Goldwirt

    Rationale: Cytotoxic drug preparation in hospital pharmacies is associated with chronic occupational exposure leading to a risk of adverse effects. The objective was to develop and validate a quantification method for the following cytotoxic drugs in environmental wipe samples: cyclophosphamide, ifosfamide, cytarabine, dacarbazine, docetaxel, paclitaxel, doxorubicin, epirubicin, etoposide, 5‐fluorouracil, gemcitabine, irinotecan, methotrexate and pemetrexed. Methods: The quantification method was developed using liquid chromatography coupled to tandem mass spectrometry and a wiping technique using viscose swabs. Linearity, accuracy, precision, limit of quantification, specificity and stability were assessed, from swab desorbed solution, to validate the analytical method, with respect to ICH guidelines. Environmental samples were collected by wiping five work surfaces of 225 cm 2 with viscose swabs, during three days. Results: The quantification method was linear over the calibration range with a lower limit of quantification ranging from 0.5 to 5.0 ng mL −1 depending on the cytotoxic drug. The intra‐day and inter‐day relative biases were below 1.5% and 13.5%, respectively. This method was successfully applied to surface‐wipe sampling and environmental contaminations ranged from 0.7 to 1840.0 ng cm −2 for the most contaminated areas. Conclusions: This quantification method for 14 cytotoxic drugs was successfully applied to environmental contamination monitoring and could therefore be a useful tool for monitoring and toxicological studies.


  • Mutagenicity assessment of environmental contaminations in a hospital centralized reconstitution unit

    by T. Chouquet, A. Acramel, H. Sauvageon, A. Plé, N. Jourdan, I. Madelaine, P. Faure, S. Mourah, L. Goldwirt